Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dapagliflozin cardiovascular effects on end-stage kidney disease (DARE-ESKD-2) trial: rationale and design.
Barreto J, Martins M, Pascoa M, Medorima STK, Bonilha I, Jesus DC, Carbonara CEM, Quadros KRS, Assato B, Campos-Staffico AM, Júnior GG, Nadruz W, de Oliveira RB, Sposito AC. Barreto J, et al. Among authors: medorima stk. Expert Opin Drug Saf. 2024 Oct 13:1-7. doi: 10.1080/14740338.2024.2412228. Online ahead of print. Expert Opin Drug Saf. 2024. PMID: 39377184
Dapagliflozin cardiovascular effects on end-stage kidney disease (DARE-ESKD-2) trial: rationale and design.
Barreto J, Martins M, Pascoa M, Medorima STK, Bonilha I, Jesus DC, Carbonara CEM, Quadros KRS, Assato B, Campos-Staffico AM, Júnior GG, Nadruz W, de Oliveira RB, Sposito AC. Barreto J, et al. Among authors: medorima stk. Res Sq [Preprint]. 2023 Oct 19:rs.3.rs-3434207. doi: 10.21203/rs.3.rs-3434207/v1. Res Sq. 2023. Update in: Expert Opin Drug Saf. 2024 Oct 13:1-7. doi: 10.1080/14740338.2024.2412228 PMID: 37886458 Free PMC article. Updated. Preprint.
Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial.
Breder I, Cunha Breder J, Bonilha I, Munhoz DB, Medorima STK, Oliveira DC, do Carmo HR, Moreira C, Kontush A, Zimetti F, Zanotti I, Carvalho LSF, Nadruz W, Muscelli E, Quinaglia T, Sposito AC; EXCEED-BHS3 Trial Investigator. Breder I, et al. Among authors: medorima stk. Ther Adv Chronic Dis. 2020 Sep 28;11:2040622320959248. doi: 10.1177/2040622320959248. eCollection 2020. Ther Adv Chronic Dis. 2020. PMID: 33062236 Free PMC article.